Clinical Trial Update: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pharmacokinetics and safety of subcutaneous ublituximab in multiple sclerosis. The study compares injection sites and autoinje…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: NOT_YET_RECRUITING